IDiyas

For the Inventor, By the Inventor

Montreal, Canada

Michael Mannion

USPTO Granted Patents = 12 


 

Average Co-Inventor Count = 9.3

ph-index = 2

Forward Citations = 19(Granted Patents)


Location History:

  • Cuthbert, CA (2010 - 2012)
  • Montreal, CA (2013 - 2015)

Company Filing History:

goldMedal12 out of 53 
 
Methylgene, Inc.
 patents

Years Active: 2010-2015

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 9018378 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2015-04-28),
2. 8907091 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2014-12-09),
3. 8906852 - Inhibitors of protein tyrosine kinase activity (2014-12-09),
4. 8846927 - Inhibitors of protein tyrosine kinase activity (2014-09-30),
5. 8759522 - Inhibitors of protein tyrosine kinase activity (2014-06-24),
6. 8729268 - Inhibitors of protein tyrosine kinase activity (2014-05-20),
7. 8440643 - Inhibitors of beta-lactamase (2013-05-14),
8. 8404846 - Inhibitors of protein tyrosine kinase activity (2013-03-26),
9. 8389541 - Inhibitors of protein tyrosine kinase activity (2013-03-05),
10. 8329726 - Inhibitors of VEGF receptor and HGF receptor signaling (2012-12-11),
11. 8093264 - Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling (2012-01-10),
12. 7790729 - Inhibitors of VEGF receptor and HGF receptor signaling (2010-09-07),

Title: Unveiling the Genius of Montreal's Inventor Michael Mannion

Introduction:

Michael Mannion is a renowned inventor based in Montreal, Canada, with an impressive portfolio of 12 patents to his name. His groundbreaking work in the field of pharmaceuticals has revolutionized the development of fused heterocyclic kinase inhibitors and compounds that inhibit protein tyrosine kinase activity.

Latest Patents:

Michael Mannion's latest patents showcase his innovative approach to drug development. One of his recent inventions includes processes and intermediates for preparing fused heterocyclic kinase inhibitors. These intermediates are instrumental in manufacturing thienopyridine-based compounds, particularly at an industrial level. Another notable patent relates to inhibitors of protein tyrosine kinase activity, specifically targeting growth factor receptors like VEGF receptors to treat cell proliferative and ophthalmic diseases.

Career Highlights:

Michael Mannion is a key figure at Methylgene, Inc., where his inventive spirit has flourished. Through his leadership and pioneering research, he has propelled the company to the forefront of pharmaceutical innovation. Mannion's expertise in developing novel compounds has earned him widespread acclaim in the scientific community and beyond.

Collaborations:

Collaboration plays a crucial role in Michael Mannion's success. Working alongside esteemed colleagues such as Arkadii Vaisburg and Stephen Claridge, Mannion has fostered a culture of innovation and excellence. Together, they have pushed the boundaries of pharmaceutical research, resulting in groundbreaking discoveries that have the potential to transform the healthcare industry.

Conclusion:

Inventor Michael Mannion's unparalleled contributions to the field of pharmaceuticals underscore his dedication to advancing scientific knowledge and improving patient care. His patents not only represent technological milestones but also attest to his unwavering commitment to innovation. As he continues to shape the future of drug discovery, Michael Mannion remains a visionary force in the world of inventions and patents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…